Cadila Pharmaceuticals, headquartered in Ahmedabad, said it had obtained the license to manufacture a generic version of Pfizer’s Covid-19 oral antiviral drug, PAXLOVID, and sell it in 95 countries, including India.
A company spokesperson said it got the green light after signing a sublicense agreement with Medicines Patent Pool (MPP), a UN-based public health organization working to increase access to medicines vital for low- and middle-income countries.
“We are delighted to partner with MPP to create a generic version of the innovative drug PAXLOVID for the global community and help reduce the health burden due to the pandemic.
“We reiterate our commitment to bringing affordable innovations to the last man in society,” Cadila Pharmaceuticals CMD Rajiv Modi said in a statement.
Pfizer’s PAXLOVID™ consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to prevent the virus from replicating, and ritonavir, which slows the breakdown of nirmatrelvir to help it stay in the body longer. higher concentrations. PAXLOVID is given as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice a day for five days.
The drug is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of the onset of symptoms.
The spokesperson said Cadila Pharmaceuticals will serve the Indian and export markets as many countries with high Covid-19 burden do not have access to effective therapy. The United States Food and Drug Administration (FDA) was the first regulatory agency to authorize the use of PAXLOVID, nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use to treat adults and pediatric patients with mild to moderate high risk Covid-19 over the age of 12, weighing at least 40 kg.
Aurobindo Pharma and Torrent Pharmaceuticals also obtained the license today.